Secondary failure of metformin monotherapy in clinical practice. - Wikidata - wikimedia - TriplyDB

Secondary failure of metformin monotherapy in clinical practice.

Secondary failure of metformin monotherapy in clinical practice.

http://www.wikidata.org/entity/Q33683607

about

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?Provider beliefs about diabetes treatment have little impact on glycemic control of their patients with diabetes Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes.Recognition of incident diabetes mellitus during an acute myocardial infarction HbA1c After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes.A clinical trial to maintain glycemic control in youth with type 2 diabetes.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus The Change in HbA1c Associated with Initial Adherence and Subsequent Change in Adherence among Diabetes Patients Newly Initiating Metformin Therapy Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial.Impact on glycated haemoglobin of a biological response-based measure of medication adherence.Linagliptin as add-on therapy to insulin for patients with type 2 diabetes The association between different A1C-based measures of glycemia and risk of cardiovascular disease hospitalization.Correlates of treatment patterns among youth with type 2 diabetes.In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Managing diabetes from first diagnosis: choosing well-tolerated therapies with durability.Diabetes therapy--focus on Asia: second-line therapy debate: insulin/secretagogues.What are the pharmacotherapy options for treating prediabetes?Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps.Clinical trials in youth-onset type 2 diabetes: needs, barriers, and options.Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes.Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycaemic control: An individual patient simulation study.New insights into the anti-diabetic actions of metformin: from the liver to the gut.Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis.Budget Impact of Introducing Linagliptin into Bosnia and Herzegovina Health Insurance Drug Reimbursement List in 2016-2018.Initial antihyperglycemic drug therapy among 241 327 adults with newly identified diabetes from 2005 through 2010: a surveillance, prevention, and management of diabetes mellitus (SUPREME-DM) study.Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs.Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus.Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm.Comparison of β-Cell Function Between Overweight/Obese Adults and Adolescents Across the Spectrum of Glycemia.Impact of Timely Treatment Intensification on Glycemic Goal Achievement in Patients With Type 2 Diabetes Failing Metformin Monotherapy.Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program.Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity.Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes.Clinical Predictors of Progressive Beta-Cell Failure in Type 2 Diabetes.Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.

P2860

Q33354192-DA2CBF37-9F96-4084-8CDC-0F7B78F35A6B Q35126777-30C9CB8B-DB0C-406C-AFE3-BA1313EDA513 Q35305506-81D74C5B-A54E-4545-905A-BD3BD54641C5 Q35629691-3C04F045-5211-4373-82E6-89C51BC61D2C Q36311680-B4BD0967-9FA8-45B1-89B6-D5EF2DD43692 Q36340078-900FBD61-61EC-4B31-8EF6-27109A392D5E Q36345951-A8F3A051-2BBB-48E2-B93A-B365CCB8D131 Q37192432-B0310F37-830C-46FF-8E62-0B2FBD853523 Q37193695-14F8523D-09B1-4159-8605-2A62F462F8B6 Q37275626-790ABF40-2392-4007-8061-103C8643FD7E Q37281205-AC2AE867-77A3-4314-8719-C4093688B226 Q37403177-21A342F9-CC62-4657-92BD-205CEC571919 Q37403191-F8A9C5A0-301F-4306-8B56-B7030F87B286 Q37577126-465CF2C1-DE5E-4926-9B8A-332AB02E80D9 Q37577162-0109E83C-A06D-4D15-A472-225944ABF5A9 Q38020015-04D793AF-B9B2-40E6-A0DD-740332DD6A35 Q38071018-B92E1A69-7D00-48A6-ADFF-7BCE2FDD5B90 Q38241464-81FEDB17-A258-4DE9-9C40-172800240F50 Q38246691-C993E899-8957-4FC0-AA47-7061BCC2A653 Q38380568-C7B2F045-83BF-4748-A1E2-86A7CD99C16E Q38387034-F235FAB0-DDF5-4724-81A7-14A5131F9DB8 Q38602464-BD0F1460-A199-4691-A09B-FA86327DA20C Q38955525-8DB327BB-ECC9-46D3-984D-72B7D70D691D Q39041261-510ACF45-ED21-4928-9D2E-FC5E8E817C37 Q40362406-C5F11689-ED55-4DCB-B250-4A70D59F91E0 Q40633336-1355F66C-5276-4BE7-BA34-658EA06441F6 Q43237434-D83C2B6B-43BB-4176-80A6-A2D894D20FCB Q44449274-94E82EBC-9C3C-4435-B1F5-BADFFCF61BC0 Q46265606-0FEBD4B8-95F1-43D9-96AF-D4F8B337768A Q46598580-E860B152-CFB0-4732-AE3A-1F5F4BF2A19A Q47122013-A404167F-F2AD-4483-AD59-5DE7357A56E2 Q47755876-04FC53EE-5DDF-47D9-A83F-46F1F5787145 Q48221716-1E443ACE-FC42-4382-BFB3-F07C48530251 Q48686005-3E0B7916-24CD-49FD-A22E-5C4AB05BA2F4 Q50067146-F9567AFB-A3E1-4370-876C-5F294663CB3C Q50168195-482B6C6A-AC59-4A31-A395-8B2844F519EF Q50988205-F162386C-1570-423D-8A3F-84A241E20EBD Q51158595-FBFC3201-A4B9-4B55-8D1F-82E4DBEFFCF9 Q51301686-F62C643F-9B1A-4AEF-89E8-634E55E0C7EF Q51357963-422D2DE9-C737-43A3-9328-57C40B84FB04

P2860

Secondary failure of metformin monotherapy in clinical practice.

http://www.wikidata.org/entity/Q33683607

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Secondary failure of metformin monotherapy in clinical practice.

@ast

Secondary failure of metformin monotherapy in clinical practice.

@en

type

label

Secondary failure of metformin monotherapy in clinical practice.

@ast

Secondary failure of metformin monotherapy in clinical practice.

@en

prefLabel

Secondary failure of metformin monotherapy in clinical practice.

@ast

Secondary failure of metformin monotherapy in clinical practice.

@en

P1433

Q33683607-E26D3C8B-8B61-4D03-A7EE-78EED362C75F

P1476

Q33683607-2BE7F783-BFA6-4BDB-AC13-69498A5AEB21

P2093

Q33683607-31D92A9F-5FC3-47B6-B464-C5C9768CB606

Q33683607-788A6916-78E3-4ACB-81EB-56E51C0D23DE

Q33683607-BA7A4CA5-6383-40F4-BDE8-345A02CE93E1

P2860

Q33683607-1AD1376A-B0A8-4A41-B279-947B8EEB7C63

Q33683607-629DD047-FA26-42FA-9586-7843988985B2

Q33683607-62E84A10-77DF-4658-B138-00DD59FC98C3

Q33683607-6D5119B9-A0FD-4348-936B-2F994D8CB7D3

Q33683607-6F64F173-4B91-43D3-8801-2866F07D8B4B

Q33683607-6F6C67E3-D04E-448E-8AFF-AF09B7CE2842

Q33683607-7C0D3DDB-F9A3-40B7-B6F0-711AE4D9EF03

Q33683607-8CA0C41A-3881-4EDF-88F7-DAD8C421DC8E

Q33683607-92B1BA6E-5F6A-4E5C-92E6-0E4741E3A1C9

Q33683607-9ECE0B99-2372-4A4B-AD9D-3FF3EF6718FD

P304

Q33683607-CC14EB8E-4C23-424C-AAF2-BC1EF61D95EC

P31

Q33683607-1CDC0FF2-9A13-42BC-A0EA-3EA72153499F

P356

Q33683607-96049EFD-35C5-44D6-8CA7-8059A9B2F8DA

P407

Q33683607-485325B1-1239-4BDA-8C7D-B376AA08207A

P433

Q33683607-3B39872A-7568-488F-A3EE-E134A837898C

P478

Q33683607-84C25CBB-326F-4673-904B-76995D4820F1

P577

Q33683607-630EBF08-3D86-4053-ADC7-4EB5E5DBB52E

P5875

Q33683607-85ECA1DF-7371-40C6-AAB4-82897238FEB6

P698

Q33683607-53C7BBB0-6273-4B25-94FD-54B0764F16C8

P921

Q33683607-83B6E2DE-8391-406E-872E-8F191114F8E4

P932

Q33683607-832FB6A3-E387-489A-934F-1F7428FF8A99

P356

P1433

P1476

Secondary failure of metformin monotherapy in clinical practice.

@en

P2093

Christopher Conner

http://www.w3.org/2001/XMLSchema#string

Gregory A Nichols

http://www.w3.org/2001/XMLSchema#string

Jonathan B Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

10-year follow-up of intensive glucose control in type 2 diabetes

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Standards of medical care in diabetes--2009.

Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%.

The burden of treatment failure in type 2 diabetes.

P304

501-506

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-1749

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40812417

http://www.w3.org/2001/XMLSchema#string

P698

20040656

http://www.w3.org/2001/XMLSchema#string

P921

P932

2827496

http://www.w3.org/2001/XMLSchema#string